Pemetrexed Injection, Powder, Lyophilized, For Solution
Product Images NDC 71288-147

Pemetrexed is a Cytotoxic Agent used for Intravenous Use only. It comes in a single-dose vial with 100mg of pemetrexed disodium, which is equivalent to 106mg of mannitol. The pH of the solution may have been adjusted with Hydrochloric acid and/or sodium hydroxide, based on requirements. The solution must be further diluted before administration. To prepare the solution, 4.2 mL of 0.9% Sodium Chloride Injection should be added to the vial, upon which it will contain 25 mg per mL of the active ingredient. The shelf life of the solution is 24 hours after reconstitution, after which the unused portion should be discarded. It should be stored at 20°C to 25°C, and reconstituted and infusion solutions must be refrigerated at 2°C to 8°C. Dosage information can be found with the accompanying literature. The container closure is not made with natural rubber latex.*

This is a description of an injectable drug called Pemetrexed for Injection, which comes in vials containing 1 gram of pemetrexed disodium and 1 gram of mannitol. The solution must be reconstituted by adding 40 mL of 0.9% Sodium Chloride Injection to achieve a concentration of 25 mg/L pemetrexed. The reconstituted solution must be diluted further before use. The infusion solution should be administered within 24 hours of initial reconstitution, and any unused portion should be discarded. The dosage information is provided in accompanying literature. The drug is stored at 20-25°C (68-77°F) with excursions permitted to 15-30°C (59-86°F). Once reconstituted, the solution should be refrigerated at 2-8°C (36-46°F). The drug is sterile, nonpyrogenic, and preservative-free, and the container closure is not made with natural rubber latex. It is a cytotoxic agent intended for intravenous use only. The manufacturer is Meitheal Pharmaceuticals, and the drug is distributed by Kindos Pharmaceuticals Co., Ltd. of Chengdu, China.*

This is a description of a drug called Pemetrexed for Injection, USP. Each vial contains 500 mg of pemetrexed disodium and 500 mg of Mannitol. Reconstitution is required by adding 20 ml of 0.9% Sodium Chloride Injection to make a solution containing 25 mg per mL pemetrexed. The reconstituted solution must be further diluted before use. The drug is a sterile, non-pyrogenic, and preservative-free solution. The drug is a cytotoxic agent for intravenous use only. The dosage instructions are available in the accompanying literature. The drug must be stored at 20° to 25°C with excursions permitted. The manufacturing company is Meileal Pharmaceuticals in Chicago, IL, and Kindos Pharmaceuticals Co.L in Chengdu, China. The container closure is not made with natural rubber latex.*

The text is a description of Pemetrexed for Injection, USP, a cytotoxic agent. Each vial contains 750 mg pemetrexed disodium equivalent to 750 mg of mannitol. Hydrochloric acid and/or sodium hydroxide may have been added to adjust pH. To reconstitute, add 30 mL of 0.9% Sodium Chloride Injection to make a solution containing 25 mg per mL pemetrexed. The reconstituted solution must be further diluted before use. Administer infusion solution within 24 hours after initial reconstitution. Discard the unused portion. The storage temperature is recommended to be 20°C to 25°C (68°F to 77°F), and reconstituted solution must be stored refrigerated at 2°C to 8°C (36°F to 46°F). It is sterile, nonpyrogenic, and preservative-free. The container closure is not made with natural rubber latex. The manufacturer is Meitheal Pharmaceuticals, and it is distributed by Kindos Pharmaceuticals Co, Li from Chengu, China. The product has an NDC code of 71288-147-50.*

This is a survival chart comparing Overall Survival rates of two different treatments, P+B+C (pemetrexed + pembrolizumab + platinum chemotherapy) and P+C (pemelrexed + plaiinum chemotherapy + placebo) in patients over time in months. The chart shows the percentage of patients who survived under each treatment at time intervals of 12, 18, 24, 30, and 36 months. The number of patients at risk is provided for each time interval.*

This appears to be a table displaying the survival time and number of patients at risk for two treatment options - Pemetrexed + Cisplatin (PC) and Gemcitabine + Cisplatin (GC). The number of patients at risk is decreasing with increasing survival time.*

This is a table showing the survival probability of two different chemotherapy treatments. The treatments are Pemetrexed + Cisplatin (PC) and Gemcitabine + Cisplatin (GC). The table includes the number of patients at risk, survival time in months, and the corresponding time points.*

This is a clinical trial data showing the survival time (in months) of patients who were administered with Pemetrexed and placebo. The patients' progress was monitored up to 40 months.*

This is a survival probability table showing the survival rate of patients treated with Pemetrexed over time. The table shows the number of patients at risk over months, ranging from 3 to 24. Patients treated with Pemetrexed are indicated in the first row, while patients that were given placebo are indicated in the second row. The table is likely part of a study or clinical trial evaluating the effectiveness of Pemetrexed as a treatment for a specific medical condition.*

This appears to be a table, displaying survival time in months and the number of patients at risk. The table compares the effects of Pemetrexed and Placebo on patients, with the number of patients at risk decreasing over time for each group. The specific data points are difficult to understand without further context.*

This appears to be a survival analysis chart showing the number of patients at risk and their survival time (in months) when treated with Pemetrexed. The chart includes the number of patients at risk for each survival time point.*

This text appears to be a graph showing survival probability of patients at risk with a certain treatment. The treatment is either Pemetrexed + Cisplatin or Cisplatin alone. The graph shows the number of patients at risk at each month interval for up to 10 months. The survival time in months is shown on the x-axis. However, the data is incomplete and inconsistent, making it difficult to draw any concrete conclusions.*